Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at Citizens on Ph2 Miss for Remlifanserin
Tweet Send to a Friend
Citizens analyst Jason Butler lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $33.00 (from $36.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




